Orforglipron
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 600
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Orforglipron Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Orforglipron Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Orforglipron Dose 3 | n/r | n/r | n/r | n/r | n/r |
| Orforglipron Dose 4 | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.